Thursday, November 21, 2024
Home Tags Ctxr

Tag: ctxr

Citius Pharma
2020 Watch List

Citius Pharma (CTXR) On The Move.

Editor / Curator -
Biotech News

Update: Biotech 5 Pack. 5 Biotech Stocks, we Expected to Double...

Editor / Curator -
All News

Citius Pharma (CTXR) Seeks Expeditious Pathway Into the Clinic, for CoronaVirus...

Editor / Curator -
Superbug News - CoronaVirus Watch List

New Report: Citius (CTXR) Trades 13 Million Shares on CoronaVirus and...

Editor / Curator -
Aphex Biocleanse, Superbug Stock Review
All News

Oh, No. Alcohol-Based Sanitizers Losing Effectiveness Against Superbugs.

Editor / Curator -
All News

VirnetX (VHC) Scores $440 Million and Citius Pharma (CTXR) Sees Market...

Editor / Curator -
Biotech News

Fortress Bio (FBIO) Inches Closer to $3.00 on Major News.

Editor / Curator -
Citius, Biotech Stock Review
Biotech News

Citius (CTXR) Achieves 50% Patient Enrollment in Phase 3 Mino-Lok® Pivotal...

Editor / Curator -
Biotech News

Okay, so What’s Next for Citius Pharma (CTXR) $1.16?

Editor / Curator -
Immunomedics, Biotech Stock Review
All News

Biotech 5 Pack. 5 Biotech Stocks We Expect to Double in...

Editor / Curator -
1234Page 3 of 4

Latest article

Nine Page Summary Report on GeoVax (GOVX)

2024 Watch List Editor / Curator -
This is a great long-term story. We’re telling you. (March 2024) When we finished writing our earlier...

GeoVax (GOVX) Provides First Half 2024 Business Update.

2024 Watch List Editor / Curator -
Award of BARDA Project NextGen contract represents a significant milestone event; Total value...

Reverse Split Mania! Solgenix (SNGX) Jumps 448% After 1:16.

All News Editor / Curator -
Can You Imagine Selling Solgenix at $2.00 yesterday. And to be honest, news wasn't all that big - such...
The Internet Stock Review is one of Wall Streets oldest newsletters covering internet technology having launched in 1999. The Biotech Stock Review is rather old too, having launched in 2002. We make our money by purchasing stock with our services, so the better our client stocks do, the better we all do. And when we're wrong, we feel the pain too! See our research reports for important disclaimer details. Content is provided by Institutional Analyst Inc., the website is managed by Revelers.IO Media Group Inc. To see if your Company qualifies for coverage, call 310-594-8062
Contact us: [email protected]
© Managed by Revelers.IO Media Group Inc.